These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 28043604)

  • 41. Treatment outcomes in multidrug-resistant tuberculosis according to pyrazinamide susceptibility.
    Park S; Jo KW; Shim TS
    Int J Tuberc Lung Dis; 2020 Feb; 24(2):233-239. PubMed ID: 32127109
    [No Abstract]   [Full Text] [Related]  

  • 42. Detection by denaturing gradient gel electrophoresis of pncA mutations associated with pyrazinamide resistance in Mycobacterium tuberculosis isolates from the United States-Mexico border region.
    McCammon MT; Gillette JS; Thomas DP; Ramaswamy SV; Rosas II; Graviss EA; Vijg J; Quitugua TN
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2210-7. PubMed ID: 15917514
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pyrazinamide-resistant mycobacterium tuberculosis isolates from Khyber Pakhtunkhwa and rpsA mutations.
    Khan MT; Malik SI; Bhatti AI; Ali S; Khan AS; Zeb MT; Nadeem T; Fazal S
    J Biol Regul Homeost Agents; 2018; 32(3):705-709. PubMed ID: 29921403
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fluoroquinolone and pyrazinamide resistance in multidrug-resistant tuberculosis.
    Pierre-Audigier C; Surcouf C; Cadet-Daniel V; Namouchi A; Heng S; Murray A; Guillard B; Gicquel B
    Int J Tuberc Lung Dis; 2012 Feb; 16(2):221-3, i-ii. PubMed ID: 22236923
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Turkey.
    Yüksel P; Tansel O
    New Microbiol; 2009 Apr; 32(2):153-8. PubMed ID: 19579692
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis.
    Becerra MC; Freeman J; Bayona J; Shin SS; Kim JY; Furin JJ; Werner B; Sloutsky A; Timperi R; Wilson ME; Pagano M; Farmer PE
    Int J Tuberc Lung Dis; 2000 Feb; 4(2):108-14. PubMed ID: 10694087
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mechanisms of Pyrazinamide Action and Resistance.
    Zhang Y; Shi W; Zhang W; Mitchison D
    Microbiol Spectr; 2013; 2(4):1-12. PubMed ID: 25530919
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characterization of pncA gene mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Mexico.
    Cuevas-Córdoba B; Xochihua-González SO; Cuellar A; Fuentes-Domínguez J; Zenteno-Cuevas R
    Infect Genet Evol; 2013 Oct; 19():330-4. PubMed ID: 23321280
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genotypic Analysis of Genes Associated with Independent Resistance and Cross-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis Clinical Isolates.
    Rueda J; Realpe T; Mejia GI; Zapata E; Rozo JC; Ferro BE; Robledo J
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7805-10. PubMed ID: 26369965
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis.
    Shi W; Chen J; Feng J; Cui P; Zhang S; Weng X; Zhang W; Zhang Y
    Emerg Microbes Infect; 2014 Aug; 3(8):e58. PubMed ID: 26038753
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.
    Young EF; Perkowski E; Malik S; Hayden JD; Durham PG; Zhong L; Welch JT; Braunstein MS; Hickey AJ
    Pharm Res; 2016 Oct; 33(10):2495-505. PubMed ID: 27351427
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria.
    Singh P; Mishra AK; Malonia SK; Chauhan DS; Sharma VD; Venkatesan K; Katoch VM
    J Commun Dis; 2006 Mar; 38(3):288-98. PubMed ID: 17373362
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multi-drug resistant Mycobacterium tuberculosis complex genetic diversity and clues on recent transmission in Punjab, Pakistan.
    Yasmin M; Gomgnimbou MK; Siddiqui RT; Refrégier G; Sola C
    Infect Genet Evol; 2014 Oct; 27():6-14. PubMed ID: 24981519
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Proficiency of drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide: the Swedish experience.
    Hoffner S; Angeby K; Sturegård E; Jönsson B; Johansson A; Sellin M; Werngren J
    Int J Tuberc Lung Dis; 2013 Nov; 17(11):1486-90. PubMed ID: 24125455
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular identification of mutations associated with anti-tuberculosis drug resistance among strains of Mycobacterium tuberculosis.
    Abbadi SH; Sameaa GA; Morlock G; Cooksey RC
    Int J Infect Dis; 2009 Nov; 13(6):673-8. PubMed ID: 19138546
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis isolated in Poland].
    Napiórkowska A; Augustynowicz-Kopeć E; Zwolska Z
    Pneumonol Alergol Pol; 2010; 78(4):256-62. PubMed ID: 20665445
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Investigation of isoniazid and ethionamide cross-resistance by whole genome sequencing and association with poor treatment outcomes of multidrug-resistant tuberculosis patients in South Africa.
    Malinga L; Brand J; Jansen van Rensburg C; Cassell G; van der Walt M
    Int J Mycobacteriol; 2016 Dec; 5 Suppl 1():S36-S37. PubMed ID: 28043598
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genotypic analysis of multidrug-resistant tuberculosis isolates from extra pulmonary tuberculosis cases in tertiary care centers in Northern India.
    Maurya AK; Nag VL; Kant S; Kushwaha RS; Dhole TN
    Int J Mycobacteriol; 2016 Dec; 5 Suppl 1():S125-S126. PubMed ID: 28043502
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitative
    Lopez JM; Zimic M; Vallejos K; Sevilla D; Quispe-Carbajal M; Roncal E; Rodríguez J; Rodríguez J; Antiparra R; Arteaga H; Gilman RH; Maruenda H; Sheen P
    J Clin Microbiol; 2023 May; 61(5):e0152222. PubMed ID: 37071032
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New mutations in pncA of in vitro selected pyrazinamide-resistant strains of Mycobacterium tuberculosis.
    Bamaga M; Zhang H; Wright DJ
    Microb Drug Resist; 2001; 7(3):223-8. PubMed ID: 11759083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.